For investors assessing a future listing, the non-dilutive funding IPO signal is often overlooked. Grants, R&D tax relief and innovation loans do not replace equity, but they can show whether a company funds innovation with discipline, protects shareholder value and understands the governance expected before public-market scrutiny.
What is non-dilutive funding?
Non-dilutive funding is capital or financial support that does not require a company to issue new shares. It can include grants, R&D tax relief, public innovation programmes, project-based subsidies and, in some circumstances, innovation loans.
For pre-IPO companies, this matters because it changes the funding mix. A company does not have to fund every stage of research, product development or technical validation through equity alone. That can reduce pressure on the cap table and help preserve ownership for existing shareholders.
“Before an IPO, investors want evidence that growth is funded carefully, not just quickly. Non-dilutive funding can help show that discipline.” – Dr Fawzi Abou-Chahine, Grant Funding Director at FI Group by EPSA
Common forms include:
| Funding type | How it works | Why investors may care |
| Grants | Public funding awarded for eligible innovation or growth projects | May indicate external review of the project’s technical and commercial case |
| R&D tax relief | Corporation tax relief or expenditure credit linked to qualifying R&D activity | Can support cash flow and reveal the quality of R&D evidence and governance |
| Innovation loans | Repayable finance designed to support late-stage innovation | Can extend runway, but should be assessed alongside cash generation and repayment capacity |
| Public sector project funding | Scheme-specific support for sectors such as clean tech, life sciences, aerospace or advanced manufacturing | Can show alignment with policy priorities and strategic markets |
Not all non-dilutive funding carries the same weight. A small one-off grant may have little bearing on an IPO case. A well-managed funding portfolio, tied to a credible R&D roadmap, can tell investors more.
FI Group by EPSA insight
FI Group by EPSA is the global leader in innovation funding and advises companies on innovation incentives, including R&D tax credits, grants and innovation loans. In the context of IPO preparation, their work helps finance teams assess how a non-dilutive funding strategy can support R&D activity, strengthen evidence standards and sit within a wider funding plan.
Why does non-dilutive funding matter before an IPO?
Non-dilutive funding matters before an IPO because it can show that a company is not relying solely on equity capital to fund growth. It can support the equity story by showing capital efficiency, evidence discipline and a more mature approach to innovation finance.
An IPO is not only a fundraising event. It is a disclosure event. Companies preparing to list must explain their business model, growth strategy, risk factors, governance, financial position and use of proceeds. Investors will test whether the company’s story is credible, repeatable and supported by evidence.
For high-growth companies with heavy R&D spend, this is especially relevant. Many businesses approaching an IPO are not yet optimised for profit. They may be investing heavily in technology, clinical validation, production capacity, AI infrastructure, regulatory approvals or international expansion. Equity capital is often necessary, but it is not always the only funding source available.
A company that has secured non-dilutive funding may be able to show that it has:
- reduced avoidable shareholder dilution
- used public funding to support high-risk R&D
- extended cash runway without relying only on new equity
- passed external technical or commercial assessment
- built internal systems for reporting, evidence and cost tracking
- linked innovation spend to defined project milestones
That combination is more persuasive than the funding amount alone.
How non-dilutive funding makes investor capital work harder
Non-dilutive funding can make investor capital work harder by using grants, R&D tax relief and other incentives to support activities that equity would otherwise need to fund.
The logic is simple. If a company raises equity to fund product development, every pound of equity is exposed to the full cost of the programme. Where appropriate non-dilutive funding is secured, part of that development cost can be supported without issuing additional shares. The company still needs strong execution, but the investor’s capital may stretch further.
This can matter in three ways.
1. Lower dilution pressure
Pre-IPO investors often care about dilution across multiple rounds. If a company can finance part of its innovation pipeline without issuing more shares, it may reduce dilution pressure before listing.
That does not automatically mean the company deserves a higher valuation. It does mean the funding strategy can support a stronger valuation narrative if the capital is material, recurring and aligned with growth.
2. More disciplined R&D planning
Competitive grants and innovation funding usually require a company to define project scope, milestones, technical objectives, costs and expected outcomes. Those requirements can encourage better internal discipline.
For investors, the value is not just that money was received. It is that the company has had to document what it is building, why it matters, how much it costs and how progress will be measured.
3. Better runway management
Non-dilutive funding can help extend the runway, especially for companies with high development costs and long commercialisation cycles. This is common in sectors such as life sciences, deep tech, climate technology, aerospace, advanced manufacturing and AI infrastructure.
Runway extension should still be assessed carefully. Grants may be paid in arrears. R&D tax relief depends on eligible expenditure and compliance. Innovation loans may add repayment obligations. Investors should examine cash timing, not only headline funding secured.
What investors should look for in a pre-IPO funding mix
Investors should look for whether non-dilutive funding is material, repeatable, well governed and connected to the company’s commercial roadmap. The strongest signal comes from funding that supports strategic execution, not isolated awards.
A useful diligence framework is:
| Investor question | What good looks like |
| Is the funding material? | It contributes meaningfully to R&D spend, runway or project delivery |
| Is it recurring or one-off? | There is a repeatable funding strategy, not accidental grant wins |
| Is it connected to the equity story? | Funding supports products, platforms or markets that matter to the IPO case |
| Are obligations understood? | Management can explain reporting, milestones, match funding, repayment or clawback terms |
| Is evidence robust? | Costs, technical work, project records and internal approvals are documented |
| Is ownership clear? | IP, contractual rights and funded assets sit in the correct entity structure |
| Is the timing reliable? | Cash receipts, tax credits or grant payments are modelled conservatively |
The strongest pre-IPO companies do not treat non-dilutive funding as a side benefit. They treat it as part of corporate finance planning.
When non-dilutive funding becomes a risk signal
Non-dilutive funding becomes a risk signal when a company cannot explain how it was secured, what obligations attach to it, or whether the underlying claims can withstand review.
Investors should be cautious where funding is presented as simple upside with no operational caveats. Public funding often comes with conditions. R&D tax relief requires technical and financial substantiation. Grants may involve monitoring, eligible cost rules and evidence requirements. Loans may require repayment even if commercialisation takes longer than planned.
Potential warning signs include:
- large R&D tax claims with weak technical evidence
- unclear project boundaries or cost apportionment
- grant awards that depend on milestones the company is unlikely to meet
- material funding that has not been reflected properly in cash flow forecasts
- reliance on one public funding source with no fallback plan
- lack of clarity around IP created through funded work
- no internal owner for grant reporting or claim documentation
- aggressive presentation of expected credits as guaranteed cash
The issue is not that non-dilutive funding is risky by default. The issue is that weak management of it can create disclosure, cash flow or credibility problems.
How funding governance supports IPO readiness
Funding governance supports IPO readiness by turning non-dilutive funding from a finance benefit into evidence of operating maturity. Investors want to see that management understands controls, reporting and risk.
This is where the connection to IPO readiness becomes clear. A company preparing to list will already be reviewing governance, internal controls, board capability, reporting processes, audited accounts and its equity story. Non-dilutive funding should sit within the same discipline.
A strong governance model should include:
A clear funding register
The company should maintain a single record of grants, tax relief claims, innovation loans and other public funding. This should include award dates, amounts, eligible costs, reporting dates, cash receipt assumptions and obligations.
Evidence mapped to each project
For R&D tax relief, the company should be able to explain the scientific or technological uncertainty, the baseline, the intended advance and the work undertaken to resolve the uncertainty. For grants, it should be able to show project delivery against scope, budget and milestones.
Finance and technical ownership
Funding should not sit only with finance or only with the technical team. A strong process usually requires both. Finance owns cost evidence and reporting. Technical leads explain the underlying project work and uncertainty.
Conservative cash flow treatment
Investors will look closely at cash timing. Grants paid in arrears, tax relief claims awaiting processing and milestone-based funding should not be treated as equivalent to cash already received.
Board visibility
Material non-dilutive funding should be visible at board level. If it is large enough to influence runway, valuation narrative or IPO preparation, it is large enough to govern properly.
FAQs
What does non-dilutive funding mean before an IPO?
Non-dilutive funding before an IPO means funding that supports the company without requiring new equity issuance. It can include grants, R&D tax relief and certain innovation loans. It may help preserve shareholder ownership and support capital efficiency.
Is non-dilutive funding always positive for IPO investors?
No. It is positive only when it is material, well documented and aligned with the company’s growth strategy. Poorly evidenced claims, grant delivery issues or repayment obligations can reduce the strength of the signal.
Can grants improve a company’s valuation before listing?
Grants do not automatically improve valuation. They may support a stronger valuation narrative where they reduce funding pressure, validate strategic projects or help finance innovation without additional dilution.
Why do R&D tax credits matter in IPO readiness?
R&D tax credits matter because they can affect cash flow, technical evidence standards and tax governance. A company preparing to list should be able to explain its claims, costs, project evidence and compliance process clearly.
What should investors ask about non-dilutive funding?
Investors should ask how much funding has been secured, when cash is expected, what obligations apply, whether claims have been reviewed, how evidence is stored and whether the funding supports the core equity story.
Official sources and further reading
London Stock Exchange, AIM IPO Checklist: guidance on IPO preparation, equity story, governance, internal processes, IP ownership and audited financials.
U.S. Securities and Exchange Commission, Investor Bulletin: Investing in an IPO: guidance on IPO registration statements, Form S-1, prospectus disclosure and investor review.
HMRC, Additional information you must submit before you claim Research and Development tax relief: guidance on R&D claim information, project descriptions, scientific or technological uncertainties and supporting evidence.
UKRI, Innovate UK guidance on funding offers and grant setup: guidance on project setup, grant offer letters, monitoring and funding conditions.